Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections
Public ClinicalTrials.gov record NCT01147640. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Double-Blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA 101/ Tazobactam and Metronidazole With That of Meropenem in Complicated Intraabdominal Infections
Study identification
- NCT ID
- NCT01147640
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Enrollment
- 122 participants
Conditions and interventions
Conditions
Interventions
- CXA-101/ tazobactam and metronidazole Drug
- meropenem plus saline placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 24, 2010
- Primary completion
- Feb 19, 2011
- Completion
- Mar 24, 2011
- Last update posted
- Oct 24, 2018
2010 – 2011
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pulmonary Consultants and Primary Care Physicians Medical Group, Inc. | Orange | California | 92868 | — |
| Los Angeles Biomedical Research Institue at Harbor UCLA Medical Center | Torrance | California | 90509 | — |
| University of Colorado Hospital | Aurora | Colorado | 88045 | — |
| Christiana Care Health System | Newark | Delaware | 19718 | — |
| Pensacola Research Consultants, Inc. | Pensacola | Florida | 32504 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| South Jersey Infectious Disease | Somers Point | New Jersey | 08244 | — |
| Metro Health Medical Center | Cleveland | Ohio | 44109 | — |
| The Ohio State University | Columbus | Ohio | 43210 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| University of Tennessee Health Science Center | Memphis | Tennessee | 38163 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01147640, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 24, 2018 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01147640 live on ClinicalTrials.gov.